Tricida (NASDAQ:TCDA) posted its quarterly earnings results on Thursday. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.19, Fidelity Earnings reports.
TCDA traded up $1.31 during midday trading on Friday, reaching $29.72. 102,280 shares of the company were exchanged, compared to its average volume of 106,502. Tricida has a one year low of $21.87 and a one year high of $40.10.
Institutional investors and hedge funds have recently modified their holdings of the business. VHCP Management II LLC bought a new position in Tricida during the second quarter worth about $28,785,000. Baker BROS. Advisors LP bought a new position in Tricida during the second quarter worth about $47,840,000. Vivo Capital LLC bought a new position in Tricida during the second quarter worth about $29,652,000. TD Asset Management Inc. bought a new position in Tricida during the second quarter worth about $574,000. Finally, Janus Henderson Group PLC bought a new position in Tricida during the second quarter worth about $299,000. Hedge funds and other institutional investors own 62.43% of the company’s stock.
TCDA has been the topic of several recent research reports. Zacks Investment Research cut Tricida from a “hold” rating to a “sell” rating in a report on Wednesday, October 10th. Goldman Sachs Group began coverage on Tricida in a report on Monday, July 23rd. They issued a “neutral” rating and a $32.00 price target on the stock. JPMorgan Chase & Co. began coverage on Tricida in a report on Monday, July 23rd. They set a “neutral” rating and a $34.00 target price on the stock. Finally, Cowen began coverage on Tricida in a report on Monday, July 23rd. They set an “outperform” rating and a $50.00 target price on the stock.
TRADEMARK VIOLATION NOTICE: This news story was published by Stock Observer and is the property of of Stock Observer. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thestockobserver.com/2018/11/10/tricida-tcda-issues-quarterly-earnings-results-beats-estimates-by-0-19-eps.html.
Tricida Company Profile
Tricida, Inc, a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease.
Read More: How analysts view the yield curve
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.